← Product Code [CBZ](/submissions/AN/subpart-b%E2%80%94diagnostic-devices/CBZ) · K970906 # PARATREND 7 MULTIPARAMETER SENIOR AND SATELLITE MONITOR SYSTEM WITH PARATREND 7 PLUS MULTIPARAMETER SENSOR (K970906) _Diametrics Medical, Ltd. · CBZ · Sep 23, 1997 · Anesthesiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/AN/subpart-b%E2%80%94diagnostic-devices/CBZ/K970906 ## Device Facts - **Applicant:** Diametrics Medical, Ltd. - **Product Code:** [CBZ](/submissions/AN/subpart-b%E2%80%94diagnostic-devices/CBZ.md) - **Decision Date:** Sep 23, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 868.1170 - **Device Class:** Class 2 - **Review Panel:** Anesthesiology ## Intended Use The Paratrend 7+ System is intended to be used in the management of the critically ill patient by providing continuous blood gas data while permitting the simultaneous monitoring of blood pressure via an external transducer. The Paratrend 7+ Multiparameter Sensor is inserted via an intravascular access device into the vascular system (e.g. radial, femoral arteries). Completion of Monitoring and Sensor Withdrawal Within the United States market, the use of this device should be limited to 72 hours. ## Device Story Intravascular catheter-based sensor system for continuous monitoring of blood gases (pO2, pCO2, pH) and temperature in critically ill patients. Inputs: blood chemistry signals via optical fiber/fluorescence quenching (pO2) and photometric absorption (pCO2, pH); temperature via thermocouple. Device transforms raw optical/thermal signals into blood gas values using internal monitor processing. Output: continuous blood gas data displayed on Senior or Satellite monitor systems; allows simultaneous blood pressure monitoring via external transducer. Used in clinical settings (ICU/critical care) by healthcare professionals. Benefits: provides real-time, continuous physiological data to assist in clinical decision-making for patient management. ## Clinical Evidence Bench testing only. Accuracy evaluated by comparing measured values against precision gas mixtures in tonometers at 37°C. Bias and precision calculated for pO2, pCO2, and pH. Linear regression analysis performed between Senior and Satellite monitor readings showed good correlation. Paired sample t-test indicated no significant difference between monitor systems at the 5% level. ## Technological Characteristics Sensor: pO2 (fiber optic, fluorescence quenching), pCO2/pH (fiber optic, photometric absorption), temperature (thermocouple). Monitor: Analog/digital processing. Rotary advancing mechanism for catheter insertion. Connectivity: Senior and Satellite monitor systems. ## Regulatory Identification An indwelling blood hydrogen ion concentration (pH) analyzer is a device that consists of a catheter-tip pH electrode and that is used to measure, in vivo, the hydrogen ion concentration (pH) in blood to aid in determining the patient's acid-base balance. ## Special Controls *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Indwelling Blood Gas Analyzers; Final Guidance for Industry and FDA.” ## Predicate Devices - Paratrend 7 Intravascular Blood Gas Monitoring System - Paratrend 7 Satellite Multi Parameter Blood Gas Monitoring System ## Reference Devices - Optex Blood Gas Monitoring System - Baxter Swan-Ganz Continuous Cardiac Output Oximetry ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K970906 # Section 12: 510(k) Summary SEP 23 1997 This section satisfies the 510(k) summary as required by 21 CFR 807-92 (C). ## Submitter Miss Jan L Walters Diametrics Medical Limited Short Street High Wycombe Bucks HP11 2QH UK Tel: +44 1494 471671 Fax: +44 1494 474890 Date of Summary: 10 March 1997 ## Device Name Proprietary: Paratrend 7 Multiparameter Senior and Satellite Monitor System with Paratrend 7 Plus Multiparameter Sensor Common: Multiparameter Catheter ## Device Classification Panel: Anaesthesiology Devices Panel Classification: Class III FDA CFR: 868-1150 Description: Analyser Gas, Carbon Dioxide, Partial Pressure, Blood Phase, Indwelling Classification No: 73CCC Short Street High Wycombe Bucks. HP11 2QH England Tel: 44 (0) 1494 471671 391 {1} # Statement of Substantial Equivalence Diametrics Medical Ltd claims substantial equivalence to products which have received FDA clearance by the Premarket Notification process. The Paratrend 7 Multiparameter Senior and Satellite Monitor Systems with Paratrend 7 Plus Multiparameter Sensor is a modification of the *Paratrend 7 Intravascular Blood Gas Monitoring System* and *Paratrend 7 Satellite Multi Parameter Blood Gas Monitoring System*. Furthermore, it is also judged to be substantially equivalent to the *Optex Blood Gas Monitoring System* and the *Baxter Swan-Ganz Continuous Cardiac Output Oximetry*. # Device Description The Paratrend 7 Plus Sensor (MPS7004P) is a modified version of the currently legally marketed device, the Paratrend 7 sensor (MPS7004). The measurement of pO₂ using an electrochemical sensor (Clark electrode) in the predicate Paratrend 7 sensor has been replaced in the Paratrend 7 Plus device by a sensor based on optical fibre/fluorescence quenching technology. All other measurement parameters are essentially unchanged. The telescopic introduction mechanism in the predicate Paratrend 7 sensor has been replaced by a rotary advancing mechanism. The application has been expanded to include venous access. # Intended Use The Paratrend 7 Plus Multiparameter Sensor is intended to be inserted via an intravascular access device into the vascular system (e.g. radial, femoral arteries). It is intended to be used in the management of the critically ill patient by providing continuous blood gas data while permitting the simultaneous monitoring of blood pressure via an external transducer. The sensor is used in conjunction with the Paratrend 7 Multiparameter Senior and/or Satellite Monitor systems. # Technological Characteristics ## Measurement Technology pO₂ : fibre optic, fluorescence quenching Temp : thermocouple pCO₂ : fibre optic, photometric absorption pH : fibre optic photometric absorption ## Monitor Technology Analogue/digital {2} # Comparison of Accuracy to the Predicate Paratrend 7 Device The device under review was manufactured under standard process conditions and calibrated on the Senior Monitor. The tonometers were maintained at 37°C and were pre-equilibrated with precision gas mixtures thereby allowing the calculation of “actual” partial pressures. The Henderson-Hasselbalch equation is used to determine the “actual” pH values in the different tonometers. The measured (displayed) values were recorded after a 20 minute equilibration time. The PDMs were then transferred to Satellite monitors and the measured readings recorded. The PDMs were then returned to the Senior monitor prior to transferring the sensor to the next equilibrated tonometer. The data were analysed by calculating the bias (the mean of the differences between the measured Paratrend 7 value and that the actual value of the equilibrated solution) and the precision (sample standard deviation of the differences). The data were collected over the relevant range of gases, as shown in the following table. The differences obtained on both Senior and Satellite systems were compared. A linear regression was then performed of the measured Senior readings vs. the measured Satellite readings. The correlation coefficient, line-intercept and line-gradient were recorded. # Conclusion The data presented above satisfies product accuracy claims and shows comparable results for both Senior and Satellite. The similarity of the two data sets can be assessed from an analysis of the difference of the Senior and Satellite differences. A paired sample t-test has been applied to the Senior and Satellite readings. The two data sets showed no significant difference at the 5% level. A linear regression analysis of the Senior data vs the Satellite data for pO₂, pH and pCO₂ readings provides further evidence of good correlation between Senior and Satellite readings. The device under review is considered substantially equivalent. {3} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 SEP 23 1997 Ms. Jan L. Walters Diametrics Medical Limited Short Street High Wycombe Bucks. HP11 2QH ENGLAND Re: K970906 Paratrend 7 Multiparameter Senior and Satellite Monitor System with Paratrend 7 Plus Multiparameter Sensor Regulatory Class: III (three) Product Code: 73 CCE Dated: June 24, 1997 Received: June 26, 1997 Dear Ms. Walters: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {4} Page 2 - Ms. Jan L. Walters This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for *in vitro* diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, ![img-0.jpeg](img-0.jpeg) Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5} 19- 9-97 13:03 ;Diametrics Medical 01494474890;#10/12 Page 1 of 1 510(k) Number (if known): K970906 Device Name: Paratrend 7+ Intravascular Blood Gas Monitoring System Indications For Use: The Paratrend 7+ System is intended to be used in the management of the critically ill patient by providing continuous blood gas data while permitting the simultaneous monitoring of blood pressure via an external transducer. The Paratrend 7+ Multiparameter Sensor is inserted via an intravascular access device into the vascular system (e.g. radial, femoral arteries). Completion of Monitoring and Sensor Withdrawal Within the United States market, the use of this device should be limited to 72 hours. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use ☐ OR Over-The-Counter Use ☐ (Optional Format 1-2-96) Al A. Carbowski (Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number _______________ --- **Source:** [https://fda.innolitics.com/submissions/AN/subpart-b%E2%80%94diagnostic-devices/CBZ/K970906](https://fda.innolitics.com/submissions/AN/subpart-b%E2%80%94diagnostic-devices/CBZ/K970906) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com